Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

853
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
853
Schemas01:42

Schemas

12.3K
A schema is a mental construct consisting of a cluster or collection of related concepts (Bartlett, 1932). There are many different types of schemata, and they all have one thing in common: schemata are a method of organizing information that allows the brain to work more efficiently. When a schema is activated, the brain makes immediate assumptions about the person or object being observed.
12.3K
The Nucleolus02:55

The Nucleolus

10.3K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.3K
Internal Receptors01:31

Internal Receptors

74.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small peptides derived from the autoinhibitory XY linker of phospholipase C-β isoforms inhibit enzyme activity and reduce inflammation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Addition of Amine-Substituted Heteroaromatic Rings to Alkynyl Bridging Ligands to Generate Phosphorescent Emitters Incorporating Iridaimidazoles with Fused Heterocyclic Rings.

Inorganic chemistry·2025
Same author

<i>In Silico</i> Assisted Identification, Synthesis, and <i>In Vitro</i> Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel.

Journal of medicinal chemistry·2024
Same author

C-H, N-H, and O-H Bond Activations to Prepare Phosphorescent Hydride-Iridium(III)-Phosphine Emitters with Photocatalytic Achievement in C-C Coupling Reactions.

Inorganic chemistry·2024
Same author

Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.

European journal of medicinal chemistry·2024
Same author

β-Lactam TRPM8 Antagonists Derived from Phe-Phenylalaninol Conjugates: Structure-Activity Relationships and Antiallodynic Activity.

International journal of molecular sciences·2023

Related Experiment Video

Updated: Jan 24, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K

Recent Progress in TRPM8 Modulation: An Update.

Rosario González-Muñiz1, M Angeles Bonache2, Cristina Martín-Escura3

  • 1Instituto de Química Médica, IQM-CSIC. Juan de la Cierva 3, 28006 Madrid, Spain. rosario.gonzalezmuniz@iqm.csic.es.

International Journal of Molecular Sciences
|May 31, 2019
PubMed
Summary

Transient Receptor Potential Melastatin subtype 8 (TRPM8) channels are key in cold sensation and various diseases. This review covers new TRPM8 modulators and structural insights for therapeutic development.

Keywords:
TRPM8agonistsantagonistsstructure

More Related Videos

Author Spotlight: Advancing 3D Coculture Systems with PVA-PCL Nanofibrous Membranes
10:08

Author Spotlight: Advancing 3D Coculture Systems with PVA-PCL Nanofibrous Membranes

Published on: December 27, 2024

797
Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

857

Related Experiment Videos

Last Updated: Jan 24, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K
Author Spotlight: Advancing 3D Coculture Systems with PVA-PCL Nanofibrous Membranes
10:08

Author Spotlight: Advancing 3D Coculture Systems with PVA-PCL Nanofibrous Membranes

Published on: December 27, 2024

797
Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

857

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • The TRPM8 channel is activated by cold and cooling agents, playing a role in thermal sensation.
  • TRPM8 is implicated in various pathologies, including cancer, pain (migraine), and dysfunction of the urinary tract, dry eye, and obesity.
  • Modulating TRPM8 activity is crucial for understanding its physiological roles and developing targeted therapies.

Purpose of the Study:

  • To review recent advancements in TRPM8 agonists and antagonists.
  • To highlight newly identified chemotypes targeting TRPM8.
  • To discuss the application of these modulators in the pharmacological characterization of TRPM8 in health and disease.

Main Methods:

  • Literature review of recent scientific publications on TRPM8.
  • Analysis of newly reported chemical structures (chemotypes) acting on TRPM8.
  • Discussion of structural data of TRPM8, including complexes with ligands and PIP2.

Main Results:

  • Recent progress in identifying novel TRPM8 agonists and antagonists has been made.
  • New chemotypes with potential therapeutic applications have been described.
  • Structural insights into TRPM8, alone and bound to ligands/PIP2, are enhancing our understanding.

Conclusions:

  • TRPM8 modulators are valuable tools for pharmacological research.
  • Understanding TRPM8 structure-activity relationships is key for drug discovery.
  • Targeting TRPM8 offers potential therapeutic strategies for a range of diseases.